The Center for Medicare and Medicaid Services (CMS) has elected to limit coverage of Aduhelm, an drug that received controversial approval from the Food and Drug Administration () last year despite calls from experts that it did not work.The drug, developed by Cambridge, Massachusetts-based, Biogen, received a green light from regulators last summer, a decision that kicked off a tumultuous period for both the agency and the company.Opponents to the drug include many doctors and scientists who criticize the failed clinical trial process and data collection practices performed by Biogen in the lead up to approval.
Load More
Load More